Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
88 hedge funds and large institutions have $655M invested in Revance Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 11 closing their positions.
705% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $269K
173% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 11
131% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 16
54% more capital invested
Capital invested by funds: $426M → $655M (+$228M)
26% more funds holding
Funds holding: 70 → 88 (+18)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$17.4M |
| 2 |
Millennium Management
New York
|
+$6.24M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$5.18M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.61M |
| 5 |
JP Morgan Chase
New York
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$23.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$8.52M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$7.22M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$4.15M |
| 5 |
Goldman Sachs
New York
|
-$2.73M |
RVNC Hedge Fund Activity: Q2 2015 in Review
88 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2015, worth a combined $655M — up 54% from $426M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RVNC positions and 11 closed out — a net gain of 19 holders — while 37 added to existing stakes and 16 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $17.4M. The largest seller was Visium Asset Management, exiting entirely with an estimated $23.1M sold.
- 88 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2015, up from 70 in Q1 2015.
- Funds reported $655M of Revance Therapeutics, Inc. stock for Q2 2015, up 54% quarter-over-quarter.
- 30 funds opened new Revance Therapeutics, Inc. positions in Q2 2015 and 11 closed out, a net change of +19 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2015 was Bank of New York Mellon, an estimated $17.4M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2015 was Visium Asset Management, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2015.